medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 6

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (6)


Abordaje diagnóstico de tumor primario desconocido: la fiebre de origen oscuro de las neoplasias

Rebolledo-García D, Contreras S, Granados-Moreno DL

Idioma: Español
Referencias bibliográficas: 35
Paginas: 896-909
Archivo PDF: 529.02 Kb.


RESUMEN

El diagnóstico de un tumor primario desconocido suele ser difícil por su comportamiento clínico-patológico, su clínica emerge tardíamente de tal manera que la integración de un protocolo diagnóstico a partir de un síntoma o hallazgo clínico inespecífico condiciona el retraso de su abordaje. Las características propias de este tumor le confieren las herramientas mínimas necesarias para abandonar tempranamente su nicho de origen, diseminándose y alojándose distante al mismo, es decir, una metástasis temprana. El desarrollo de técnicas moleculares que sobrepasan la patología clásica ha sido una herramienta invaluable para su clasificación, teniendo la intención absoluta de separar los potencialmente sensibles a un tratamiento oncológico de los que no lo son. Sin rasgos distintivos que te permitan suponerlo, ante un clínico avezado la sospecha inicial de esta entidad es la mejor herramienta diagnóstica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Almeda-Valdés P, Pichardo-Bahena R. Cáncer de primario desconocido. Revisión basada en evidencias. Medigraphic 2003(10)3:1-8.

  2. Tomuleasa C, Zaharie F, et al. How to Diagnose and treat a cancer of unknown primary site. J Gastrointestin Liver Dis March 2017;26(1):69-79.

  3. A. Krämer, H. Löffler. Chapter 1: Defining cancer of unknown primary. In: Krämer A, Löffler H, editors. Switzerland: Springer International Publishing, 2016;1-4.

  4. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362- 374. Doi: 10.1038/nrc1075.

  5. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011;147:275-292. doi:10.1016/j.cell.2011.09.024.

  6. Massard C, et al. Carcinomas of an unknown primary origin—diagnosis and treatment. Nat Rev Clin Oncol 2011;8:701-710. doi:10.1038/nrclinonc.2011.158.

  7. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13.

  8. Pavlidis, N. & Fizazi, K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009;69:271-278.

  9. Hemminki K. Chapter 2: Epidemiology, risk factors, and survival in CUP: Pointers to disease mechanisms. Krämer A, Löffler H, editors. Switzerland: Springer, 2016;5-22.

  10. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 2012;23:1854-63.

  11. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, et al. Occupation and cancer – follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48:646-790.

  12. Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, et al. Intracellular signaling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 cases. Ann Oncol 2012;23(10):2725-30.

  13. Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, et al. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastasis 2013;30(4):431-9.

  14. Stoyianni A, Pentheroudakis G, Benjamin H, Cervantes A, Ashkenazi K, Lazaridis G, et al. Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA. Clin Transl Oncol 2014 Aug;16(8):725-31. doi: 10.1007/s12094-013-1139-5.

  15. Correa P, Piazuelo BM. The gastric precancerous cascade. J Dig Dis 2012;13:2-9.

  16. Varadhachary GR, Raberm MN. Cancer of unknown primary site. N Engl J Med 2014;371:757-65.

  17. Pavlidis N, Briasoulis E, Pentheroudakis G & ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;(Suppl. 5):v228-v231.

  18. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379:1428-35.

  19. Pavlidis N, Khaled H, Gaafar R, et al. A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. J Adv Res 2015;6:375-382.

  20. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-85.

  21. Burglin SA, Hess S, et al. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. Medicine 2017;96:16.

  22. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36:8-37.

  23. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-193.

  24. Stella GM, Senetta R, et al. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med 2012;10:12.

  25. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of diagnostic algorithm. Clin Cancer Res 2005;11(10):3766- 3772.

  26. Greco FA, Oien K, Erlander M, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2011.

  27. Tothill RW, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-4040.

  28. Horlings HM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26:4435-4441.

  29. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.

  30. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAX): a systemic review of published evidence. Breast Cancer Res Treat 2010;119:1-11.

  31. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumor, ovarian cancer counterpart or a distinct entity? A systemic review. Crit Rev Oncol Hematol 2010;75:27-42.

  32. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009;11:340-8.

  33. Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and comparative study with other neuroendocrine tumours. Cancer Treat Rev 2011;37:358-65.

  34. Hübner G. Chapter 8: Treatment of disseminated CUP. Krämer A, Löffler H, editors. Switzerland: Springer Int., 2016;113-121.

  35. Gatalica Z, et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 2014;5:12440-12447.




2020     |     www.medigraphic.com